News tagged with gleevec
Doctors say cancer drug costs are too high
More than 100 doctors from around the world have signed a letter decrying the high cost of cancer drugs which reach $100,000 per year or more, and calling for pharmaceutical companies to ease prices.
Medications
Apr 26, 2013 |
5 / 5 (4) |
2
New technology spots drugs' early impact on cancer
A new preclinical technology enables researchers to quickly determine if a particular treatment is effective against gastrointestinal stromal tumors (GISTs), providing a boost to animal research and possibly patient care, ...
Cancer
Apr 09, 2013 |
not rated yet |
0
Drug maker Novartis loses India patent battle (Update)
India's Supreme Court on Monday rejected drug maker Novartis AG's attempt to patent an updated version of a cancer drug in a landmark decision that health activists say ensures poor patients around the world ...
Medications
Apr 01, 2013 |
5 / 5 (3) |
0
India's top court to deliver Novartis judgment
India's Supreme Court is to rule Monday on a landmark patent case involving Swiss drugmaker Novartis AG that focuses on demands by major companies that their investments be protected, against Indian companies ...
Medications
Mar 31, 2013 |
not rated yet |
0
FDA expands approval of Bayer cancer drug (Update)
The U.S. Food and Drug Administration on Monday expanded approval of a Bayer cancer pill to treat tumors of the intestinal tract that do not respond to other treatments.
Medications
Feb 25, 2013 |
not rated yet |
0
Cancer drug a possible treatment for multiple sclerosis
(Medical Xpress)—A drug that is currently used for cancer can relieve and slow down the progression of the autoimmune disease multiple sclerosis (MS) in rats, according to a new study published in PLOS ONE. The discovery, which ...
Medical research
Feb 21, 2013 |
4 / 5 (1) |
0
|
Antibody hinders growth of Gleevec-resistant gastrointestinal tumors in lab tests
An antibody that binds to a molecule on the surface of a rare but deadly tumor of the gastrointestinal tract inhibits the growth of the cancer cells in mice, according to researchers at the Stanford University School of Medicine.
Cancer
Feb 04, 2013 |
4 / 5 (2) |
0
|
Gleevec's latest approval is for pediatric cancer
(HealthDay)—The anti-cancer drug Gleevec (imatinib) has received new U.S. Food and Drug Administration approval to treat the most common type of pediatric cancer, affecting some 2,900 children each year, the agency said ...
Cancer
Jan 25, 2013 |
not rated yet |
0
Drug targets hard-to-reach leukemia stem cells responsible for relapses
Researchers at the University of California, San Diego School of Medicine have discovered that hard-to-reach, drug-resistant leukemia stem cells (LSCs) that overexpress multiple pro-survival protein forms ...
Cancer
Jan 17, 2013 |
3.7 / 5 (3) |
0
|
Indian court to rule on generic drug industry
(AP)—From Africa's crowded AIDS clinics to the malarial jungles of Southeast Asia, the lives of millions of ill people in the developing world are hanging in the balance ahead of a legal ruling that will ...
Medications
Jan 04, 2013 |
not rated yet |
0
New drug overcomes resistance in patients with rare sarcoma
A new targeted drug demonstrated its ability to control metastatic gastrointestinal stromal tumor, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies, report ...
Cancer
Nov 21, 2012 |
5 / 5 (1) |
0
|
Researchers report first effective treatment of tumors arising from common genetic disease NF1
Physician-researchers at Indiana University School of Medicine have reported the first effective therapy for a class of previously untreatable and potentially life-threatening tumors often found in children.
Cancer
Nov 01, 2012 |
3 / 5 (1) |
0
|
Researcher investigate 2-drug synergy to treat drug-resistant chronic myeloid leukemia
(Medical Xpress)—An interdisciplinary team of researchers has dissected a case of synergy in drug-resistant chronic myeloid leukemia to understand the mechanism by which two drugs, danusertib and bosutinib, work together ...
Cancer
Oct 24, 2012 |
not rated yet |
0
|
Kinase test may yield big gains for drug-resistant cancers
In a paper published today in the journal Cell, a team from the University of North Carolina at Chapel Hill unveils the first broad-based test for activation of protein kinases "en masse", enabling measur ...
Cancer
Apr 12, 2012 |
5 / 5 (1) |
0
|
To prevent leukemia's dreaded return, go for the stem cells
Researchers reporting in the April Cell Stem Cell, a Cell Press publication, have found a way to stop leukemia stem cells in their tracks. The advance in mice suggests that a combination approach to therapy might stamp out ch ...
Cancer
Apr 05, 2012 |
4.7 / 5 (3) |
0
Imatinib
Imatinib (originally STI571) is a drug used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia/Latin America) as its mesylate salt, imatinib mesilate (INN). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and some other diseases. By 2011, Gleevec has been FDA approved to treat ten different cancers. In CML, the tyrosine kinase enzyme ABL is locked in its activated form. It induces the abnormal phenotypes of CML: excessive proliferation and high white blood cell count. Imatinib binds to the site of tyrosine kinase activity, and prevents its activity, thereby causing tumor cell apoptosis.
Imatinib is the first member of a new class of agents that act by specifically inhibiting a certain enzyme that is characteristic of a particular cancer cell, rather than non-specifically inhibiting and killing all rapidly dividing cells, and served as a model for other targeted therapy modalities through tyrosine kinase inhibition.
For more information about Imatinib, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
